Lundbeck today announced that it has signed an agreement with Kyowa Hakko Kirin Co, Ltd (Kyowa Hakko Kirin) providing Lundbeck with exclusive rights to develop and commercialise the adenosine A2a antagonist KW-6356.
Lundbeck will also have the right to further select compounds as either back-up or additional indication compounds. Adenosine A2a antagonists have potential applications in a wide range of therapeutic indications, including Parkinson’s disease. Kyowa Hakko Kirin will retain rights to develop and commercialise the compounds in Japan and the Asian region.
Kyowa Hakko Kirin will receive an upfront payment, development and commercial milestones, as well as royalties on net sales from Lundbeck.
KW-6356 is in early development and is a selective, high-affinity and long-lasting antagonist of the adenosine A2a receptor conferring strong efficacy in various disease models.
The agreement is an important supplement to Lundbeck’s commitment to provide new innovative medicines in the CNS field in areas with high unmet need.
“We are pleased with the conclusion of this agreement and have been very impressed with the achievements at Kyowa Hakko Kirin to design and discover novel A2a antagonists. We have high confidence in the potential of the compounds to become new drugs which will become important supplements to our development pipeline” says Peter H Andersen, Executive Vice President of Research at Lundbeck.